Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,526 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non Insulin Dependent Diabetes Mellitus Clear all
Completed Not applicable Interventional Results available

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT05785832
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Completed No phase listed Observational Results available

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes

NCT01341067
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Rocky Mountain Diabetes and Osteoporosis Center
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional

The Acute Effects of Specialty Coffee on Cognitive Function in People With Type 2 Diabetes

NCT07420699
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Coffee
Other
Lead sponsor
University of Reading
Other
Eligibility
30 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Post Prandial Individual Responses to Different Foods

NCT06989164
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2, Healthy
Interventions
Post prandial testing
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Bethanechol on Glucose Homeostasis

NCT01434901
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 15, 2026, 9:03 PM EDT
Completed No phase listed Observational

Pediatric Type 1 Diabetes and Retinopathy

NCT02691312
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Digital Retinography System
Device
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 26 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
De Leon Springs, Florida • Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional

A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children

NCT01146314
View directory record Official record
Conditions
Pediatric Obesity, Type 2 Diabetes, Metabolic Syndrome
Interventions
Family Focused Lifestyle Intervention
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
8 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 15, 2026, 9:03 PM EDT
Terminated Phase 3 Interventional

Pyridorin in Diabetic Nephropathy

NCT02156843
View directory record Official record
Conditions
Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
Pyridorin, Placebo
Drug
Lead sponsor
NephroGenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

NCT00700817
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 15, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Continuous Glucose Monitoring for Self-Management of Type 2 Diabetes in Young Adults

NCT07065721
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Continuous glucose monitor
Device
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Comparing High and Normal Protein Diets for the Dietary Remission of Type 2 Diabetes

NCT03832933
View directory record Official record
Conditions
Diabetes Type 2, Obesity, Diet Modification
Interventions
High Protein Diet, Standard Protein Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 15, 2026, 9:03 PM EDT
Not listed Not applicable Interventional

Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes

NCT05826678
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitor, Finger stick glucose monitoring
Device · Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Evaluating a Type 2 Diabetes Prevention Program

NCT05822648
View directory record Official record
Conditions
Type 2 Diabetes, PreDiabetes
Interventions
Project Health, Educational Video Control
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 15, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional

Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes

NCT00332085
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Chromium Picolinate
Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Kenmore, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

NCT01794143
View directory record Official record
Conditions
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions
Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
Drug
Lead sponsor
GRADE Study Group
Other
Eligibility
30 Years and older
Enrollment
7,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Not listed Not applicable Interventional

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus

NCT05302050
View directory record Official record
Conditions
Diabetes Type 2
Interventions
BT-001, Control Mobile Application
Device
Lead sponsor
Better Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

NCT02725593
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 24 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 15, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

NCT06593314
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Message with EchoGo, Standard Message
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Not listed Not applicable Interventional

Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

NCT05266625
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BT-001, Control App
Behavioral · Other
Lead sponsor
Better Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • New Orleans, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

CGM Use in Children With Type 2 Diabetes

NCT04721158
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia Due to Type 2 Diabetes Mellitus
Interventions
Continuous glucose monitor
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 15, 2026, 9:03 PM EDT
Not listed Early Phase 1 Interventional

Automated SMS-Based Appointment Validation Tool

NCT01671189
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Adult-onset Diabetes
Interventions
SMS Reminder Software Tool
Other
Lead sponsor
Medic Mobile
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

NCT00323414
View directory record Official record
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 4 Interventional

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

NCT01267448
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Hyperglycemia
Interventions
Glipizide XL, Saxagliptin + Metformin XR, Metformin XR
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543
View directory record Official record
Conditions
Diabetes, Coronary Artery Disease
Interventions
ALT-2074
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 15, 2026, 9:03 PM EDT